SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ANDRX-Reaffirm Outperform Recommendation-Gruntal Research
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: PAUL ROBERT ST. ONGE who wrote (14)11/14/1996 8:10:00 PM
From: James Silverman   of 23
 
Paul Robert St. Onge wrote:
It appears to be that Andrx will share at least half the royalties, and I would expect a continued relationship with Sepracor. Yes, the Gatt ruling has clouded the drug horizon for many companies, including
Sepracor & Andrx. I have to do further research on the deal in order
to advise, my opinion on the situation. The anlaysis is obviously focused on the European market,
======================================
First, Paul, ADRX will AT BEST receive equal royalties as SEPR. The drug is not necessarily only geared towards the European markets. As I stated, SEPR is using it as a potential negotiating tool with Hoechst. They placed "intended for european markets" in the release pretty conspicuously. Part of an agreement could possibly include rights to the once daily for U.S. markets as well. We will not know what the story is until SEPR and Hoechst settle the European patents.
Should Hoechst win european rights, all bets are off.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News